Keyword: Roivant Sciences
David Hung's decision to join Axovant after selling Medivation to Pfizer for $14 billion now looks more like a gamble that isn't paying off.
Axovant’s run of bad news shows no signs of letting up, with negative results in a phase 2b trial spelling the end for lead candidate intepirdine.
Datavant will partner its 150 data sets with the three organizations' unique capabilities to drive clinical trial intelligence.
Biogen executive Kress jumped to Syntimmune, Mendlein will guide Moderna's strategy and former FDA CIO Perakslis joined Roivant's Datavant.
Eric Perakslis' experience with Takeda will help facilitate a new collaboration between the two companies.
Roivant’s Vivek Ramaswamy didn't sugarcoat its Alzheimer’s flop but said his company won't back away from the field.
The deal sees AstraZeneca join Novartis among Mereo’s shareholders and further its efforts to offload deprioritized drugs.
The deal gives Roivant, Axovant’s parent company, another part-developed, unloved drug to try to turn into a star.
Vivek Ramaswamy’s Roivant has just put another sizable block of cash behind a hepatitis B program in development at Canada’s Arbutus Biopharma.
Andrew Witty jumped into biotech venture capital, Aerie poached another exec from Alcon, Roivant tapped Silicon Valley vet to run trial AI company.